Drug intelligence / Profile preview

RTG-2024

Development stage: Preclinical
Lead developer: RetinalGenix Technologies

Overview

RTG-2024 is an investigational therapeutic candidate being developed by RetinalGenix Technologies for the treatment of Alzheimer's disease and associated dementia. Currently in the preclinical stage, the drug is designed to target the underlying molecular and cellular changes that drive disease progression, rather than merely addressing symptoms. RetinalGenix's approach integrates the use of high-resolution retinal imaging and pharmacogenetic mapping to identify patients and monitor treatment efficacy. A provisional patent for the drug was filed in November 2023, and it is currently at the pre-IND stage of development.

Beyond the preview

Go deeper on RTG-2024.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RTG-2024.

Explore the full profile